Uveitis Secondary to Sarcoidosis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Uveitis secondary to sarcoidosis is inflammation of the uveal tract (the middle layer of the eye that includes the iris, ciliary body, and choroid) that occurs as a manifestation of sarcoidosis, a multisystem granulomatous disease of unknown cause. The eye is involved in roughly 15–25 % of sarcoidosis patients, making ocular sarcoidosis one of the most common extra‑pulmonary presentations.

Although sarcoidosis can affect anyone, it most frequently occurs in adults aged 20–40, with a higher incidence in African‑American women in the United States (incidence ≈ 17 per 100,000) compared with white populations (≈ 5 per 100,000) <sup>[1][2]</sup>. When the disease involves the eye, the typical presentation is bilateral, chronic, and can lead to vision‑threatening complications if not treated promptly.

Symptoms

The symptoms of uveitis secondary to sarcoidosis vary with the anatomic location (anterior, intermediate, posterior, or panuveitis) and may develop gradually.

• Eye pain – often a dull ache that worsens with eye movement; more common in anterior uveitis.
• Redness – especially around the cornea (ciliary injection) in anterior disease.
• Photophobia – heightened sensitivity to light.
• Blurred or decreased vision – may affect one or both eyes; can be sudden (posterior involvement) or progressive.
• Floaters – tiny, moving specks or cobweb‑like shadows caused by inflammation in the vitreous.
• Halos around lights – due to corneal edema.
• Dry eye sensation – secondary to reduced tear production.
• Headache – can accompany ocular pain.
• Peripheral vision loss – when the retina or optic nerve is involved.
• Black spots or scotomas – localized visual field defects.

Because sarcoidosis often affects other organs, patients may also have systemic symptoms such as cough, shortness of breath, skin lesions, or joint pain, which can help clinicians suspect a systemic cause for the uveitis.

Causes and Risk Factors

Underlying cause

Sarcoidosis is characterized by non‑caseating granulomas that can form in virtually any organ. The exact trigger is unknown, but prevailing theories involve an exaggerated immune response to an unidentified antigen (infectious, occupational, or environmental). The granulomatous inflammation can extend to ocular structures, producing uveitis.

Risk factors for developing ocular involvement

• Age 20–40 – peak incidence of systemic sarcoidosis.
• Female sex – women are 1.5–2 times more likely to develop sarcoidosis and ocular disease.
• African‑American ethnicity – higher prevalence and more severe disease.
• Elevated serum angiotensin‑converting enzyme (ACE) or lysozyme – markers of active granulomatous disease.
• Previous pulmonary or cutaneous sarcoidosis – Indicates systemic spread.
• Smoking – May increase the risk of chronic ocular inflammation.

Diagnosis

Diagnosis relies on a combination of clinical eye examination, systemic work‑up, and imaging. The goal is to confirm uveitis, identify sarcoidosis as the underlying cause, and rule out mimicking conditions (e.g., tuberculosis, syphilis, Behçet disease).

Ophthalmic evaluation

• Slit‑lamp biomicroscopy – detects cells in the anterior chamber, keratic precipitates, and vitreous haze.
• Fundus examination (indirect ophthalmoscopy) – evaluates the retina, optic disc, and choroid for granulomas, vasculitis, or cystoid macular edema.
• Optical coherence tomography (OCT) – high‑resolution imaging of the macula and optic nerve; detects subtle edema or retinal thickness changes.
• Fluorescein angiography (FA) or Indocyanine Green Angiography (ICGA) – highlights retinal or choroidal vascular leakage typical of sarcoid uveitis.

Systemic investigations

• Chest radiograph or high‑resolution CT – looks for hilar lymphadenopathy, a classic sarcoid finding.
• Serum ACE and lysozyme levels – elevated in ~60 % of active sarcoidosis; not diagnostic alone.
• Laboratory exclusion tests – Quantiferon‑TB, syphilis serology, and ANA panel to rule out other causes.
• Biopsy of accessible tissue (e.g., skin, lymph node, or conjunctival) confirming non‑caseating granulomas is the gold standard when diagnosis is uncertain.

Diagnostic criteria

According to the International Workshop on Ocular Sarcoidosis (IWOS), a “probable” ocular sarcoidosis diagnosis can be made when: (1) characteristic ocular signs are present, (2) systemic investigations suggest sarcoidosis, and (3) alternative diagnoses are excluded. A “definite” diagnosis requires histologic confirmation.

Treatment Options

Management aims to control intra‑ocular inflammation, preserve vision, and treat systemic disease. Therapy is usually step‑laddered, beginning with topical agents and advancing to systemic immunosuppression when needed.

First‑line (local) therapy

• Topical corticosteroid drops (e.g., prednisolone acetate 1 %) – mainstay for isolated anterior uveitis; tapered over weeks.
• Cycloplegic agents (e.g., homatropine) – relieve pain from ciliary spasm and prevent posterior synechiae.
• Topical non‑steroidal anti‑inflammatory drugs (NSAIDs) – adjunct for mild inflammation.

Intermediate or posterior involvement

• Periocular (sub‑Tennon) corticosteroid injections – depot effect for 4–6 weeks.
• Intravitreal sustained‑release steroids (e.g., dexamethasone implant – Ozurdex) – useful for macular edema.

Systemic therapy (required in >30 % of cases)

• Prednisone – oral dose 0.5–1 mg/kg/day with gradual taper; frontline for acute control.
• Steroid‑sparing immunomodulators – introduced when long‑term steroids are needed:
  • Methotrexate 15–25 mg weekly (with folic acid supplement)
  • Mycophenolate mofetil 1–2 g twice daily
  • Azathioprine 2–2.5 mg/kg/day
• Biologic agents for refractory disease:
  • Adalimumab (anti‑TNF‑α) – FDA‑approved for non‑infectious uveitis.
  • Infliximab – considered when adalimumab fails.

Adjunctive measures

• Artificial tears and lubricating ointments for dry eye.
• IOP‑lowering agents if steroids raise intra‑ocular pressure.
• Regular monitoring of liver function, blood counts, and renal function when using systemic immunosuppressants.

Lifestyle & supportive care

Smoking cessation, balanced nutrition, and regular exercise can modestly improve systemic immune regulation. Patients should avoid unprotected exposure to known ocular irritants (e.g., dust, chemicals) and wear UV‑blocking sunglasses.

Living with Uveitis Secondary to Sarcoidosis

Daily management tips

• Medication adherence – keep a daily log; use pill organizers and set reminders.
• Eye‑drop technique – wash hands, tilt head back, pull down lower eyelid, apply drop, close eye gently for 1 minute.
• Regular follow‑up – at least every 3 months while active; more frequent (monthly) during flare‑ups.
• Visual rehabilitation – if cataract or macular edema develops, low‑vision aids (magnifiers, high‑contrast reading glasses) can improve quality of life.
• Protective eyewear – sunglasses with 100 % UV protection reduce photophobia and protect against glare.
• Systemic health monitoring – annual chest imaging, pulmonary function tests, and blood work to track sarcoidosis activity.
• Stress management – chronic inflammation can be worsened by stress; mindfulness, yoga, or counseling are beneficial.

Support resources

Consider joining patient organizations such as the Sarcoidosis Foundation (sarcoidosisfoundation.org) or the American Uveitis Society; they provide educational material, support groups, and updates on clinical trials.

Prevention

Because sarcoidosis is not preventable, the focus is on early detection and minimizing flare triggers:

• Promptly evaluate any new eye redness, pain, or visual change—early treatment reduces scarring.
• Control systemic sarcoidosis with regular rheumatology follow‑up, which lowers the likelihood of ocular relapse.
• Avoid smoking and limit exposure to occupational dust or silica, both linked to more aggressive sarcoid disease.
• Maintain a healthy weight and a diet rich in omega‑3 fatty acids (found in fish, flaxseed) which have anti‑inflammatory properties.

Complications

If inflammation is not adequately controlled, several sight‑threatening complications can develop:

• Cataract – steroid use and chronic inflammation accelerate lens opacification.
• Glaucoma – secondary to corticosteroid‑induced ocular hypertension.
• Cystoid macular edema (CME) – fluid accumulation in the macula causing central vision loss.
• Epiretinal membrane or vitreoretinal traction – can cause distortion of vision.
• Choroidal granulomas – may scar and produce permanent scotomas.
• Optic nerve edema or atrophy – leads to irreversible visual field defects.
• Band keratopathy – calcium deposition in the cornea, causing glare and decreased acuity.

According to the National Eye Institute, up to 40 % of patients with chronic sarcoid uveitis develop at least one of these complications, underscoring the need for diligent monitoring <sup>[3]</sup>.

When to Seek Emergency Care

References

1. Mayo Clinic. Sarcoidosis. 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. Sarcoidosis Surveillance Data. 2022. https://www.cdc.gov
3. National Eye Institute. Uveitis Fact Sheet. 2021. https://www.nei.nih.gov
4. International Workshop on Ocular Sarcoidosis (IWOS). Diagnostic criteria for ocular sarcoidosis. *Ocular Immunology & Inflammation*. 2020;28(3):317‑329.
5. American Academy of Ophthalmology. Uveitis Preferred Practice Pattern. 2022. https://www.aao.org
6. World Health Organization. Global Burden of Sarcoidosis. 2021.

```